Langerhans cell histiocytosis as a clonal disease of mononuclear phagocyte system

Langerhans cell histiocytosis (LCH) belongs to histiocytic proliferative diseases, which are rare in clinical practice; however they pose significant challenges both for their diagnosis and choice of therapeutic strategies. Histiocytic diseases the scope oncology; nevertheless, at diagnostic stage patients referred pediatricians or dermatologists. That is why interdisciplinary interaction various specialties common approaches classification, treatment important management with disorders.
 Accumulation studies on LCH pathophysiology has promoted development new algorithms methods. After fact MAPK signal pathway activation had been established, potential target therapy was identified. Neoplastic nature hypothesized. If confirmed, we can expect actual being elaborated, particular, predict disease depending tumor clone mutation type. The unique characteristics including proliferate clonality (presumable neoplastic nature), course spontaneous regression frequent relapses tropism certain tissues (target organs) make up grounds further in-depth disease.